This project is funded by:
Skin and soft tissue infections (SSTIs) are among the most prevalent bacterial infections encountered in clinical practice, yet they pose significant therapeutic challenges. Chronic SSTIs, often complicated by biofilm formation, require long-term treatment, with current therapeutic approaches heavily dependent on systemic antibiotics. However, oral antibiotics are associated with gastrointestinal side effects and disruption of the gut microbiota, which has been shown to exacerbate antibiotic resistance. These limitations highlight the urgent need for innovative, localised antibiotic delivery systems that can effectively address these therapeutic obstacles while minimising systemic exposure.
This project aims to develop a targeted, antibiotic-loaded hydrogel-coated nanogel system to deliver the antibiotic linezolid directly to infection sites. The dual-layer design of this system includes an outer hydrogel layer that disrupts bacterial biofilms and an inner nanogel core that encapsulates the antibiotic, allowing for controlled, sustained release of the encapsulated drug. This targeted approach also keeps the antibiotic localised to the infection area, reducing systemic side effects and helping to preserve gut health. In this project, nanogels will be synthesised to effectively carry linezolid, hydrogel-coatings will be manufactured for biofilm penetration and in vitro testing will be performed to evaluate the system’s stability and efficacy.
This innovative delivery system is expected to significantly improve SSTI treatments by enhancing antibiotic effectiveness against resistant bacteria and reducing adverse effects. Its biocompatibility also makes it safe for wound care applications, offering a promising solution to manage chronic infections, surgical site infections, and other complications associated with biofilms and antibiotic resistance. Therefore, this targeted approach has the potential to improve treatment outcomes and advance antimicrobial stewardship.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Biomedical Sciences, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission. If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship. In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
Our fully funded PhD scholarships will cover tuition fees and provide a maintenance allowance of £19,237 (tbc) per annum for three years (subject to satisfactory academic performance). A Research Training Support Grant (RTSG) of £900 per annum is also available.
These scholarships, funded via the Department for the Economy (DfE) and the Vice Chancellor’s Research Scholarships (VCRS), are open to applicants worldwide, regardless of residency or domicile.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
Due consideration should be given to financing your studies.
[1] R. G. Frykberg and J. Banks, “Challenges in the Treatment of Chronic Wounds,” Adv Wound Care (New Rochelle), vol. 4, no. 9, pp. 560–582, Sep. 2015, doi: 10.1089/wound.2015.0635.
[2] Yue, B. R. Dong, M. Yang, X. Chen, T. Wu, and G. J. Liu, “Linezolid versus vancomycin for skin and soft tissue infections,” Cochrane Database of Systematic Reviews, vol. 2016, no. 1, Jan. 2016, doi: 10.1002/14651858.CD008056.pub3.
[3] L. E. Lamberte and W. van Schaik, “Antibiotic resistance in the commensal human gut microbiota,” Curr Opin Microbiol, vol. 68, p. 102150, Aug. 2022, doi: 10.1016/j.mib.2022.102150.
[4] C. Li, S. R. Obireddy, and W. F. Lai, “Preparation and use of nanogels as carriers of drugs,” Drug Deliv, vol. 28, no. 1, p. 1594, 2021, doi: 10.1080/10717544.2021.1955042.
[5] K. S. Soni, S. S. Desale, and T. K. Bronich, “Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation,” Journal of Controlled Release, vol. 240, pp. 109–126, Oct. 2016, doi: 10.1016/j.jconrel.2015.11.009.
[6] D. Keskin, G. Zu, A. M. Forson, L. Tromp, J. Sjollema, and P. van Rijn, “Nanogels: A novel approach in antimicrobial delivery systems and antimicrobial coatings,” Bioact Mater, vol. 6, no. 10, pp. 3634–3657, Oct. 2021, doi: 10.1016/j.bioactmat.2021.03.004.
Submission deadline
Monday 24 February 2025
04:00PM
Interview Date
24 March - 4 April 2025
Preferred student start date
15 September 2025
Telephone
Contact by phone
Email
Contact by email